This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.

Inclusion Criteria:

• Type 2 DM patients
• Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit
• FPG ≤ 270mg/dL at screening visit
• Patients who consent to participate in this trial by written Informed Consent Form

Exclusion Criteria:

• Type 1 DM or secondary diabetes
• Subjects who are administrating insulin or need to insulin therapy
• History of oral anti-hyperglycemic drugs within 6 weeks before screening visit
• Body mass index < 20 kg/m2 or > 40.0kg/m2
• Subjects who are assessed to be inappropriate for this trial by investigator